Cost-Effectiveness and Outcomes Research Setting value to what we do.

Slides:



Advertisements
Similar presentations
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlikeLicense. Your use of this material constitutes acceptance of that license.
Advertisements

ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
Introduction to Pharmacoeconomics
Cost-benefit and cost-effectiveness analysis: applications to health care programs and policies Greg Mason PRA Inc. and University of Manitoba October.
Community Diagnosis.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Economic Analysis and Management Todd Wagner, PhD.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol and Health: Current Evidence March-April 2006.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark.
Schneider Institute for Health Policy Heller School Brandeis University September Donald S. Shepard, Ph.D. Schneider Institute for Health Policy.
Cost Effectiveness. Cost-Effectiveness and Outcomes Research Setting value to what we do.
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older Dana P. Goldman, Federico Girosi et al. American Journal of Public Health November.
Drug and Therapeutics Committee
University of Minnesota Medical Technology Evaluation and Market Research Course: MILI/PUBH 6589 Spring Semester, 2012 Stephen T. Parente, Ph.D. $ $ Carlson.
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Chapter 4: Economic Efficiency and Cost Benefit Analysis 1.Economic Efficiency 2.Cost Benefit Analysis.
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Assessing cost-effectiveness – what is an ICER?- Incremental analysis
Strengthening partnerships: A National Voluntary Health Agency’s initiatives in managed care Sarah L. Sampsel, MPH* Lisa M. Carlson, MPH, CHES* Michele.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Cost Effectiveness Analysis To Enhance Mammography Use Dave Alvey Paul Moley.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
1 Cost-effectiveness analysis : concepts and example from the FIOCRUZ- INSERM programme related to screening strategies of TB in jails of Rio 03/08/2006.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
BIOE 301 Lecture Thirteen. HIV/AIDS Vaccine Update.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
PHAR 310: Pharmacoeconomics
M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Lecture Thirteen Biomedical Engineering for Global Health.
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
Phaedra Corso, Ph.D. Associate Professor College of Public Health University of Georgia Program Evaluation from an Economic Perspective.
Measuring Efficiency CRJS 4466EA. Introduction It is very important to understand the effectiveness of a program, as we have discovered in all earlier.
Quality Measurement and Gender Differences in Managed Care Populations with Chronic Diseases Ann F. Chou Carol Weisman Arlene Bierman Sarah Hudson Scholle.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. September 14, 2011.
Cardiovascular Disease Healthy Kansans 2010 Steering Committee Meeting April 22, 2005.
Make Nutrition Services Count: Cost-Effectiveness Research & Outcomes Research.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
Promoting high quality, cost effective drug therapy throughout the Military Health System Identification and Use of Published Health Economic Evaluations.
Flagship Program on Health Sector Reform and Sustainable Financing.
Investing in a healthy community: making the most of NICE’s ROI tools Judith Richardson Health & Social Care Directorate.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
BIOE 301 Lecture Sixteen. Review of Lectures What is the goal of cancer screening? Successful cancer screening examples? Can screening hurt more.
CRJS 4466 PROGRAM & POLICY EVALUATION LECTURE #6 Evaluation projects Questions?
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
Presentation Developed for the Academy of Managed Care Pharmacy
A Cost-Effectiveness Analysis of Maternal Genotyping to Guide Treatment in Postnatal Patients.
Chapter 7: Epidemiology of Chronic Diseases. “The Change You Like to See….” (1 of 3) Chronic diseases result from prolongation of acute illness. – With.
Chapter 14 Economic Analysis of Clinical and Managerial Interventions Copyright 2015 Health Administration Press.
Understanding Health Economics Nicola Cooper, PhD Professor of Healthcare Evaluation Research Department of Health Sciences University of Leicester
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
$Carlson School of Management, Department of Healthcare Management
Economic Evaluation of Health Interventions Basic Concepts
NAPLEX preparation: Biostatistics
Biomedical Engineering for Global Health
BIOE 301 Lecture Sixteen.
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Cost-Effectiveness and Outcomes Research Setting value to what we do

n n Define CE terms n n Review methods of evaluation in health care n n Review examples n n Identify activities that may promote CE studies Objectives:

n n What it is - What is Cost-Effectiveness? n What it is not-

n n What it is - “a method for evaluating the health outcomes and resource costs of health interventions” Russell, et al., JAMA 1996;276:1172 What is Cost-Effectiveness?

Interventions –Nutrition Support –MNT Protocols – Presence of the RD on the health care team, in the public health jurisdiction, etc.

What is Cost-Effectiveness? Outcomes in CEA –Traditional Medical Outcomes –Resource Costs –Expanded definition Patient centered outcomes Quality of life; Client satisfaction

What is Cost-Effectiveness? Cost-Savings Cheaper bang Cost-Benefit Analysis All benefits cost in dollars ?? Putting dollar value on life years What it is not - n n What it is -

Health Care Expenditure as a Share of Gross National Product (%) Zweifel P: Health Economics, 1997

n n Outcome The result of the performance (or nonperformance) of a function or process(es). JCAHO 1996 n n Outcome Indicator Measures what happens (or does not happen) to a patient after something is done (or not done) to the patient. NLHI Terms

n n Cost Benefit Analysis An analytic tool for estimating the net social benefit of a program or intervention as the incremental benefit of the program less the incremental cost, with all benefits and costs measured in dollars. Cost Effectiveness in Health and Medicine. Gold, Martha, et al  1996 University Press Terms

n n Cost Effectiveness An analytic tool in which costs and effects of a program and at least one alternative are calculated and presented in a ratio of incremental costs to incremental effects. Effects are health outcomes such as cases of a disease presented, years of life gained or quality adjusted life years rather than monetary measures as in cost benefit analysis. Cost Effectiveness in Health and Medicine. Gold, Martha, et al  1996 University Press Terms

n n QALY “Quality-adjusted life year” “A measure of health outcome which assigns to each period of time a weight, ranging from 0 to 1, corresponding to the health-related quality of life during that period, where a weight of 1 corresponds to optimum health and a weight of 0 corresponds to a health state judged equivalent to death: these are then aggregated across time periods.” Gold 1996 Terms

n n DFLE “Disability-free life expectancy” Life expectancy free of class I (or worse) disability Disability classes based on person- trade off method

Terms n n DALE “Disability-adjusted life expectancy” HL x = L x ( 1 - P ix D ix ) Where: HL x =the number of years of healthy life lived at age x L x = the number of years of life lived at age x from a life table P ix =the prevalence of disabling sequelae j at age x D ix =the disability severity weight for disabling sequelae j at age x

n n Discounting The process of converting future dollars and future health outcomes to their present values. (Gold 1996) n n Bootstrapping A simulation method for deriving nonparametric estimates of variances of interest (e.g. the variance in the C/E ratio) from a data set. (Gold 1996) n n Bayesian method A branch of statistics that uses prior information on beliefs for estimation and inference. (Gold 1996) Terms

Objectives: n n Define CE terms n n Review methods of evaluation in health care n n Review examples n n Identify activities that may promote CE studies

n Outcomes Research –Process Identify the outcome (what we effect) Set a clear definition of the outcome –Implementation Measure Analyze Evaluate Features of Cost Effectiveness

Methods of Evaluation in Health Care: CEA Method of evaluation would be cost- effectiveness analysis (CEA). Only for mutually exclusive projects. t 1 CEA = costs in units of money benefits in mmHg and t 2 CEA = costs in units of money benefits in additional life years Zweifel P: Health Economics, 1997

Methods of Evaluation in Health Care Limitations of CEA n n Implies that it is not relevant who obtains the additional life years n n It does not lend itself to the evaluation of projects with several different (positive) effects. n n Provides a rank order of preference among mutually exclusive projects, it does not answer the question which of the projects should be realized and which should not Zweifel P: Health Economics, 1997

Methods of Evaluation in Health Care: Cost Utility Analysis Method of evaluation that takes account of the multidimensionality of the concept ‘health’ by trying to encompass all effects of an intervention - prolonging life and changing health status. t CUA = costs in units of money benefits in QALYs The index value may be interpreted as ‘QALYs’ gained. Again, only for mutually exclusive projects. Unlike CEA, suitable for comparing medical interventions of heterogeneous kind and purpose Zweifel P: Health Economics, 1997

Methods of Evaluation in Health Care: Cost Benefit Analysis Zweifel P: Health Economics, 1997 Monetary equivalents are assigned to prolongations of life and change of health status. t CBA = costs in units of money benefits in units of money

Methods of Evaluation in Health Care: Zweifel P: Health Economics, 1997 Unlike cost-benefit analysis, cost- effectiveness analysis and cost-utility analysis circumvent the problem of monetary evaluation of life and health. However, they provide only a relative evaluation of mutually exclusive projects, while CBA permits evaluation of each project on its own.

Objectives n n Define CE terms n n Review methods of evaluation in health care n n Review examples n n Identify activities that may promote CE studies

n n What is the question (intervention)? –Compared to what? n n Who is the decision maker? n n Over what time period for study? n n What is (are) the unit of outcome? Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Fundamental Health Economic Questions

Hoch JS: Health Econ. 11: 415–430 (2002), Published online 31 January 2002 in Wiley InterScience (

Intervention -- Weight Reduction Program Comparing usual care to dietitian consult Your Effects usual Your $ < usual A B Your $ > usual C D What can be said about A, B, C, and D? D -- Need for incremental cost-effectiveness Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Incremental Economic Analyses: 4 Possible Situations

Dietitian Usual Care Costs $2,500 $2,200 Effects 15 lbs 10 lbs n n What is the additional cost for an additional unit of gain? < ($2, ,200)/(15lbs-10lbs) = $300/5 or $60 for each additional pound lost. Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Incremental Cost-effectiveness

Dietitian Usual Care Costs $2,500 $2,200 Effects 20% 16% reduction in Hemoglobin A1c What is the additional cost for an additional unit of gain? Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Incremental Cost-effectiveness

Dietitian Usual Care Costs $2,500 $2,200 Effects 20% 16% n n ($ )/(20-16% reduction in HbA1c) n n $300/4% reduction in HbA1c n n $75/1% reduction in HbA1c Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Incremental Cost-effectiveness

League Tables progressive listing of costs per unit of effectiveness/outcome Unit of Outcome: Cost per Life Year Saved –Hypertension screening < 40 year male$9,800/LY < 40 year female$45,869/LY –Mammography 55-65yr women$44,550/LY –Pap screening (Pap Net) 20-65y$122,888/LY –Exercise ECG 40 yr male$135,116/LY –Exercise ECG 40 yr female$364,170/LY Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Cost-Effectiveness League Tables

n n American Society for Internal Medicine and American College of Physicians used CEA in recommendations concerning: –hypertension –exercise ECG –screening < breast < prostate < cervical Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Are CEA Studies Being Used?

n n MAJOR midwest hospital with strong ties to managed care organizations and industry n n Used it over last few years for policy –hepatitis B screening for neonates –Smoking cessation –cystic fibrosis –flu inoculation reminders –anticoagulation clinic –lipid management –some drug formulary decisions Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA Are CEA Studies Being Used?

Activities on CE Lewin Study n n A study at Group Health Cooperative in Puget Sound Area n n Covered dietitian services as a supplemental benefit for Medicare enrollees covered under risk contract n n Examined use and costs over time of services in this Medicare population with diabetes and CVD who did and did not use RD services Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA

Activities on CE Lewin Study n n For DM patients using RD services hospital admissions were reduced by 9.5% and MD visits by 23.5% n n For CVD the use of RD services was associated with an 8.6% decrease in hospital utilization and a 16.9% decrease in MD visits. Judith Barr, ScD; Director, National Education and Research Center for Outcomes Assessment in Healthcare Northeastern University, Boston MA

Barriers and Limitations Expectations Training Support Outcomes difficult to measure Time of follow-up Co-Morbidities Research training

Strengths Documentation of worth Benchmark for change

Objectives: n n Define CE terms n n Review methods of evaluation in health care n n Review examples n n Identify activities that may promote CE studies